Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Chugai Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Novo Nordisk

Details:

Under the terms of agreement, Novo Nordisk will receive the rights to use several Chugai’s antibody engineering technologies for their research activities and optional rights for the development and marketing of therapeutic antibodies applying those technologies.

Lead Product(s): Antibodies

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Novo Nordisk

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement October 21, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY